Literature DB >> 9415709

Enhanced stimulatory adenylyl cyclase signaling during opioid dependence is associated with a reduction in palmitoylated Gs alpha.

H Ammer1, R Schulz.   

Abstract

Chronic opioid treatment of stably mu-opioid receptor transfected human mammary epidermoid A431 carcinoma cells (clone A431/mu 13) results in sensitization of adenylyl cyclase (AC), a cellular adaptation associated with drug dependence. Up-regulation of AC is characterized by significantly increased levels of both basal and post-receptor-stimulated effector activities, which develop without any apparent change in the quantity of stimulatory G proteins and the maximum catalytic activity of AC. Here, we report that detergent extracts from membranes of chronically morphine-treated (10 microM; 2 days) A431/mu 13 cells display higher stimulatory AC activities as assessed in the S49cyc- reconstitution assay. This finding is most likely due to an increased functional activity of Gs alpha because the addition of exogenous G beta gamma subunits, which per se stimulate AC in S49cyc- membranes, failed to affect the difference in reconstitutive AC activity. Moreover, both chemical depalmitoylation by hydroxylamine and inhibition of palmitoyl-CoA transferase in vivo by tunicamycin treatment incresed the reconstitutive activity of detergent extracts and eliminated the differences between native and opioid-dependent cells, indicating that the increase in stimulatory activity is due to depalmitoylation of Gs alpha. Indeed, metabolic labelling studies with [3H]palmitic acid revealed that chronic opioid treatment reduces considerably the fraction of palmitoylated Gs alpha in the plasma membrane. Furthermore, high affinity [3H]forskolin binding experiments demonstrated that depalmitoylated Gs alpha is able to associated directly with AC during the state of opioid dependence even without preceding receptor activation. These results suggest that post-translational palmitoylation of Gs alpha provides a potential regulator of transmembrane signaling. Moreover, accumulation of the depalmitoylated form of Gs alpha in the plasma membrane as reported herein may contribute to the increase in stimulatory AC signaling, as is characteristic for the state of opioid dependence.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9415709     DOI: 10.1124/mol.52.6.993

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  5 in total

1.  Plasma membrane cholesterol level and agonist-induced internalization of δ-opioid receptors; colocalization study with intracellular membrane markers of Rab family.

Authors:  Jana Brejchova; Miroslava Vosahlikova; Lenka Roubalova; Marco Parenti; Mario Mauri; Oleksandr Chernyavskiy; Petr Svoboda
Journal:  J Bioenerg Biomembr       Date:  2016-07-13       Impact factor: 2.945

2.  Parallel modulation of receptor for activated C kinase 1 and protein kinase C-alpha and beta isoforms in brains of morphine-treated rats.

Authors:  P V Escribá; J A García-Sevilla
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

3.  Ser/ Thr residues at α3/β5 loop of Gαs are important in morphine-induced adenylyl cyclase sensitization but not mitogen-activated protein kinase phosphorylation.

Authors:  Mohammad Seyedabadi; Seyed Nasser Ostad; Paul R Albert; Ahmad R Dehpour; Reza Rahimian; Mahmoud Ghazi-Khansari; Mohammad H Ghahremani
Journal:  FEBS J       Date:  2012-01-13       Impact factor: 5.542

4.  Selective activation of Galphao by D2L dopamine receptors in NS20Y neuroblastoma cells.

Authors:  V J Watts; B L Wiens; M G Cumbay; M N Vu; R L Neve; K A Neve
Journal:  J Neurosci       Date:  1998-11-01       Impact factor: 6.167

5.  Determination of μ-, δ- and κ-opioid receptors in forebrain cortex of rats exposed to morphine for 10 days: Comparison with animals after 20 days of morphine withdrawal.

Authors:  Hana Ujcikova; Martina Hlouskova; Kristina Cechova; Katerina Stolarova; Lenka Roubalova; Petr Svoboda
Journal:  PLoS One       Date:  2017-10-20       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.